Jampol LM, et al. - This trial was performed in order to evaluate the systemic vascular endothelial growth factor (VEGF)-A levels following the treatment with intravitreous aflibercept, bevacizumab, or ranibizumab. At 4 weeks, the decreases in plasma free-VEGF levels were greater following treatment with aflibercept or bevacizumab compared with ranibizumab. A greater decrease was observed in bevacizumab vs ranibizumab at 52 and 104 weeks. Similar changes in VEGF levels after stopping injections were suggested by the results from 2 subgroups of participants who did not receive injections within at least 1 month and 2 months before collection. If the VEGF levels returned to normal when the drug was cleared from the system or if the presence of the drug affected the assay's ability to accurately measure free VEGF remained unknown. Findings did not report any significant relationships between VEGF concentration and systemic factors.